Strategic partnerships Cagent Vascular has recently forged a strategic partnership with 3comma Medical and is actively pursuing growth capital, signaling an openness to distributor and integration collaborations that can expand market reach and accelerate adoption of the Serranator technology.

Product expansion The launch of multiple Serranator variants including SL-PRO indicates a broader product portfolio targeting CLTI and pedal disease, presenting opportunities to upsell to existing vascular clinics and to capture adjacent endovascular market segments.

Commercial leadership Appointment of a Chief Commercial Officer in 2025 suggests a strengthened go-to-market strategy, enabling focused outreach to hospitals, surgical centers, and vascular specialists and improving lead generation and sales execution.

Growth financing Securing $15M in growth capital from Trinity Capital supports scaling manufacturing, sales, and clinical education efforts, signaling readiness to support higher order volumes, training, and field service for new customers.

Clinical and outcomes focus Serranator technology emphasizes improved lumen gain and reduced recoil in PAD and CLTI interventions, which can be positioned to procurement teams on cost-of-care improvements, long-term patient outcomes, and potential lifecycle savings.